Chief Executive Officer
Khoso Baluch was appointed Chief Executive Officer in October 2016. Mr. Baluch has built and led successful U.S. and international commercial teams in the primary care, specialty and hospital segments, launching leading products including Cialis, Byetta, Insulin devices, Cimzia, Vimpat and Neupro. During the 24 years Mr. Baluch worked for Eli Lilly & Co, he held international positions in general management, business development, market access and product leadership, and spanning Europe, the Middle East and the United States. At Lilly, as Diabetes Worldwide Franchise head, he had responsibility for guiding pipeline products from Phase 3 to completion on the market. He oversaw a team of nearly 130 people responsible for the medical, regulatory, legal, supply chain, marketing, pricing and reimbursement aspects of drug launches in the U.S. and globally. Following his tenure at Lilly, Mr. Baluch held multiple positions at UCB, the global biopharmaceutical company, as Senior Vice President & Chief Marketing Officer and most recently serving as Senior Vice President & President European Middle East & Africa (EMEA) Region. Since 2013, Mr. Baluch has been a board member of Poxel, a French publically traded Biotech Company.
Executive Vice President and General Counsel
Phoebe Mounts was appointed Executive Vice President and General Counsel in May 2019. She leads the Company’s legal, compliance and regulatory affairs activities. Prior to joining CorMedix, Dr. Mounts was a partner at the law firm Morgan Lewis and Bockius LLP where since 2013 she advised the Company with respect to its FDA regulatory strategies for Defencath™ and taurolidine. Dr. Mounts is a graduate of Georgetown University Law Center, prior to which she was on the faculty of the Johns Hopkins University School of Public Health for 16 years, specializing in molecular biology and infectious disease. She received her Ph.D. in molecular biology from the University of Edinburgh in Scotland.
Executive Vice President and Chief Financial Officer
Matt David was appointed Executive Vice President and Chief Financial Officer in May 2020. He leads the Company’s finance and investor relations activities. Prior to joining CorMedix, Dr. David was Head of Strategy at Ovid Therapeutics and spent the majority of his career in healthcare investment banking roles where he advised life sciences companies on a broad range of financing and strategic transactions. Earlier in his career, Dr. David spent time as a research analyst covering the pharma sector. Dr. David received his M.D. from NYU School of Medicine and his undergraduate degree from Dartmouth College.
Executive Vice President, Technical Operations
Jack Armstrong joined CorMedix in October 2014. He has more than 40 years of experience in the pharmaceutical industry with broad cross-functional experience in all facets of supply chain and quality assurance, and has held a number of general management positions. Most recently, he was President of Correvio, a private company supplying product to more than 60 countries. Prior to that, Mr. Armstrong was President and CEO of Genaera Corporation, Senior Vice President of Urocor Corporation, CEO of Mills Biopharma, President of Endo (subsidiary of DuPont Merck), President of World-wide Manufacturing for DuPont Merck, and Vice President Operation for Marion/Marion Merrill Dow. He has also held roles in manufacturing, quality assurance, and integrated business systems development, all of which have led to significant experience in business development
Executive Vice President and Head of Clinical Operations
Liz Masson-Hurlburt serves as our Executive Vice President and Head of Clinical Operations. Prior to that, she held several progressive management roles in clinical operations, most recently at Gemphire Therapeutics, as Vice President, Clinical Operations. Responsible for strategic and operational development activities, Liz has a passion for growing and developing highly engaged teams and assuring the highest standards for program execution. Liz received her B.A. in Leadership and Organizational Management from Bay Path College.
Adviser Chief Medical Officer
Paul Chew, M.D., has been a Consultant Adviser Chief Medical Officer at CorMedix, Inc. since May 2018. He previously served as Group Chief Medical Officer, Senior Vice President and Head of Sanofi R&D North America Hub of Sanofi-Aventis U.S. LLC. from 2007 to 2016. Prior to Sanofi U.S. , Dr. Chew served as Vice President, Global Head of Metabolism & Diabetes at Aventis Pharmaceuticals from 2001 to 2004. He is a member of the PhRMA Science & Regulatory Affairs Executive Committee and the Institute of Medicine Value & Science-Driven Healthcare Roundtable. He has a substantial history of working with the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) including lead sponsor representation at FDA Advisory Committees and EMA Scientific Advisory Groups. Dr. Chew received his medical degree from The Johns Hopkins School of Medicine. Dr. Chew has spent more than 20 years at the Johns Hopkins University and School of Medicine, where he received his B.Sc. in Human Biology, completed his residency, and held various faculty positions.